{"id":"NCT04607980","sponsor":"Amgen","briefTitle":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-11","primaryCompletion":"2022-01-13","completion":"2022-06-03","firstPosted":"2020-10-29","resultsPosted":"2023-12-15","lastUpdate":"2024-12-12"},"enrollment":563,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"ABP 654","otherNames":[]},{"type":"DRUG","name":"Ustekinumab","otherNames":["StelaraÂ®"]}],"arms":[{"label":"Treatment Group A (ABP 654)","type":"EXPERIMENTAL"},{"label":"Treatment Group B (Ustekinumab - ABP 654)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"PASI Percent Change From Baseline to Week 12","timeFrame":"Baseline (Day 1 [Week 0]) and Week 12","effectByArm":[{"arm":"Treatment Group A (ABP 654)","deltaMin":81.92,"sd":19.872},{"arm":"Treatment Group B (Ustekinumab)","deltaMin":81.91,"sd":19.611}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":84,"countries":["United States","Canada","Estonia","Germany","Hungary","Latvia","Lithuania","Poland"]},"refs":{"pmids":["39442018"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":280},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Proteinuria"]}}